On October 11th, during the 14th EUGMS congress (Berlin, Germany), there was a dedicated symposium on the SPRINTT project.

The chairman was prof. Roberto Bernabei, the Principal Investigator of the SPRINTT project.

In this occasion, prof Francesco Landi presented the baseline data from the clinical trial, whereas dr. Emanuele Marzetti described the Biomarker Ancillary Study: rationale, methods and expected outcomes. Finally dr. Daniel Rooks talked about anti-sarcopenic drugs in the pipeline.